.jpeg)
{{ variable.name }}
Anamulin is a new, oral, selective ghrelin receptor agonist developed and produced by Japan's Ono Pharmaceutical Company. It is mainly used to treat cancer cachexia.
1. Common name:Anamorelin Hydrochloride
2. Trade name:ADLUMIZTable ts)
3. English name:ADLUMIZ Tablets
It is suitable for the treatment of cancer cachexia (cancercachexia) in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer.
1. Specifications: Each tablet contains 50 mg of anamulin hydrochloride.
2. Properties: Film-coated tablets, light yellow in color, with a long diameter of about 14.1mm, a short diameter of about 6.6mm, a thickness of about 5.2mm, and a mass of about 364mg.
Each tablet contains 50 mg of anamulin hydrochloride.
The usual dosage for adults is 100 mg (i.e. 2 tablets) once a day, which needs to be taken orally on an empty stomach.
If the weight does not increase or the appetite does not improve after 3 weeks of medication, the medication should be stopped.
It is not recommended to take the medication for more than 12 weeks, and the need to continue taking the medication needs to be evaluated regularly.
1. Medication time: It should be taken on an empty stomach and avoid eating within 1 hour after taking the medication.
2. Missed dose: It is not clearly stated. It is recommended to take a supplementary dose or skip it according to the doctor's advice.
3. Vomiting: If you vomit after taking the medicine, it is not recommended to take a supplement and you should wait for the next time to take the medicine.
4. Monitoring requirements: During the medication period, electrocardiogram, blood pressure, heart rate, electrolytes, liver function, blood sugar, etc. need to be monitored regularly.
1. Patients with hepatic insufficiency: It is contraindicated in patients with moderate to severe hepatic insufficiency (Child-Pugh B, C).
2. Patients with renal insufficiency: It can be used for patients with mild to moderate renal insufficiency. Data for patients with severe renal insufficiency are limited and caution is required.
3. Elderly people: Due to decreased physiological functions, medication needs to be used with caution.
4. Pregnant women: Use only when the benefits outweigh the risks.
5. Breastfeeding women: Need to weigh the pros and cons of medication and breastfeeding.
6. Children: No relevant clinical trials have been conducted and use is not recommended.
1. Common side effects (≥5%): Inhibition of stimulating conduction system (10.7%), hyperglycemia (4.3%), abnormal liver function (6.4%), lymphopenia, nausea, diarrhea, fatigue, etc.
2. Other possible side effects: Abnormal electrocardiogram, atrioventricular block, tachycardia, hypotension, rash, dry mouth, blurred vision, etc.
It is prohibited for the following patients:
1. Those who are allergic to the ingredients of this product;
2. Patients with congestive heart failure, myocardial infarction, and angina pectoris;
3. Severe conduction system disorders (such as complete atrioventricular conduction) block);
4. Those who are taking clarithromycin, itraconazole, posaconazole, ritonavir, cobicistat, emtricitabine and other drugs;
5. Those with moderate to severe hepatic insufficiency;
6. Those with gastrointestinal obstruction or organic abnormalities that make oral intake difficult.
1. Contraindicated combination: Strong CYP3A4 inhibitors (such as clarithromycin, itraconazole, ritonavir, etc.) will significantly increase the blood concentration of this drug and increase the risk of side effects.
2. Use with caution:
Antiarrhythmic drugs, beta-blockers, anti-tumor drugs with cardiotoxicity (such as anthracyclines);
Drugs that can prolong the QT interval (such as imipramine);
Moderate CYP3A4 inhibitors (such as erythromycin, diltiazem);
Grapefruit juice (inhibits CYP3A4);
CYP3A4 inducers (such as carbamazepine, rifampicin, St. John's wort) may reduce the efficacy of this drug.
Stored at room temperature, the validity period is 4 years. (Storage method and validity period)
Manufacturer: Ono Pharmaceutical Co., Ltd. (OnoPharmaceuticalCo.,Ltd.)